Plain-English translation of NCT07470073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CT1190B CAR-T cell injection for people with acute lymphoblastic leukemia (a type of blood cancer) that has come back or stopped responding to chemotherapy. The medication uses specially modified immune cells that are designed to recognize and attack cancer cells. Researchers want to find the safest and most effective dose of this treatment, and they're enrolling up to 36 patients in different age groups to see how well it works.
When acute lymphoblastic leukemia comes back or stops responding to standard chemotherapy, options become very limited and the outlook becomes serious. This medication offers a new approach by training a patient's own immune cells to fight the cancer, and this trial will help doctors understand whether it can help patients who have run out of other treatment options.
You likely qualify if…
You likely don't qualify if…
You would receive an infusion of the CT1190B CAR-T cell treatment—a one-time or limited number of doses depending on which dose level you're assigned to. The study is divided into two phases: a dose-escalation phase (where researchers find the safest dose) and a dose-expansion phase (where they confirm that dose works). Adults and adolescents receive different dose levels based on age and body weight. You would have regular clinic visits for blood tests, physical exams, and monitoring of how your body responds to the treatment over several months.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China